HARMONi-GI1 phase 3 trial of ivonescimab + chemo in 1L advanced #BTC
-OS 14.9 vs 12.1 mos HR 0.75 p 0.0031
-PFS 8.4 vs 5.8 mos HR 0.61 p<0.0001
-ORR 53.8 vs 32.5% p<0.0001
A new standard of care in China. Do we need a trial in Western countries?
#ESMO26
#ESMOAmbassadors @myESMO